|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
|
31732494 |
2020 |
|
Rasmussen Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of adenosine A2A receptor and downregulation of GLT1 is associated with neuronal cell death in Rasmussen's encephalitis.
|
31353670 |
2020 |
|
Malignant neoplasm of kidney
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
|
31732494 |
2020 |
|
Childhood Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
|
31732494 |
2020 |
|
Rasmussen subacute encephalitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of adenosine A2A receptor and downregulation of GLT1 is associated with neuronal cell death in Rasmussen's encephalitis.
|
31353670 |
2020 |
|
Anxiety Disorders
|
0.390 |
Biomarker
|
group |
BEFREE |
Altogether, the present findings suggested that the ADORA2A gene and the interaction of ADORA2A and DRD2 genes may play a role in anxiety disorders in children and adolescents with ADHD.
|
30946941 |
2019 |
|
Schizophrenia
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to examine the relationship between adenosine A2A receptor (<i>ADORA2A</i>) single nucleotide polymorphisms and schizophrenia in the North Chinese Han population.
|
31695381 |
2019 |
|
Depressive disorder
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our data support an important role for ADORA2A rs2298383 SNP in clinical heterogeneity associated with depression.
|
30511252 |
2019 |
|
Rheumatoid Arthritis
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether tagging ADORA2A and ADORA3 polymorphisms influences methotrexate treatment in RA.
|
31140226 |
2019 |
|
Sleeplessness
|
0.320 |
GeneticVariation
|
phenotype |
BEFREE |
We found that at caffeine levels higher than 300 mg/day, total sleep time (TST) decreased (<i>F</i> = 13.9, <i>p</i> < 0.01), with an increase of insomnia (ORa [95%CI] = 1.5 [1.1-1.9]) and sleep complaints (ORa [95%CI] = 1.9 [1.1-3.3]), whatever the ADORA2A polymorphism.
|
31817803 |
2019 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the current edition, Fujioka and colleagues report on four Japanese patients with Parkinson disease (PD) and severe postural abnormalities treated with istradefylline (adenosine A2A receptor antagonist); further, dopamine agonists were with- drawn.
|
31469906 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tozadenant is one of the selective adenosine A2a receptor antagonists with a potential to be a new Parkinson's disease (PD) therapeutic drug.
|
30987056 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that the ecto-5'-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease models coordinatively contribute to the elevated adenosine signalling.
|
30689733 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinson's Disease.
|
31354407 |
2019 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study aimed to examine whether functional single nucleotide polymorphisms (SNPs) in 1976T > C (ADORA2A; rs5751876) and -163C > A (CYP1A2; rs762551) influence the effect of caffeine on the postprandial glucose (GLU) response to a carbohydrate meal.
|
31324842 |
2019 |
|
Caffeine related disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Caffeine increased the protein levels of A<sub>1</sub>R without altering ADORA1 mRNA and was devoid of effects on A<sub>2A</sub>R density or ADORA2A mRNA levels.
|
31563462 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We measured the changes in blood pressure (BP) and calculation speed upon coffee intake, stratifying with gene polymorphisms, e.g., those in adenosine A<sub>2A</sub> receptor (ADORA2A) and cytochrome P450 (CYP) 1A2, and daily caffeine consumption (≤90 mg/day and >90 mg/day).
|
30773300 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Our work suggests that administration of caffeine and anti-PD1 mAb harness the therapeutic potential of effector T cells in vivo possibly due to combined blockade of PD1 and adenosine-A2A receptor pathway.
|
31711939 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Caffeine is one of the most extensively consumed stimulants in the world and has been suggested to induce wakefulness by antagonizing the function of the adenosine A2A receptor.
|
30860473 |
2019 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found that at caffeine levels higher than 300 mg/day, total sleep time (TST) decreased (<i>F</i> = 13.9, <i>p</i> < 0.01), with an increase of insomnia (ORa [95%CI] = 1.5 [1.1-1.9]) and sleep complaints (ORa [95%CI] = 1.9 [1.1-3.3]), whatever the ADORA2A polymorphism.
|
31817803 |
2019 |
|
Mental Depression
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Our data support an important role for ADORA2A rs2298383 SNP in clinical heterogeneity associated with depression.
|
30511252 |
2019 |
|
Depressed mood
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
Our data support an important role for ADORA2A rs2298383 SNP in clinical heterogeneity associated with depression.
|
30511252 |
2019 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings indicate that Adora2a-mediated signaling in endothelial cells mediates obesity-induced BBB breakdown, and implicate cerebrovascular dysfunction as the mechanism for deficits in synaptic plasticity and cognition with obesity and diabetes.
|
30886019 |
2019 |
|
Diabetes Mellitus
|
0.020 |
Biomarker
|
group |
BEFREE |
These findings indicate that Adora2a-mediated signaling in endothelial cells mediates obesity-induced BBB breakdown, and implicate cerebrovascular dysfunction as the mechanism for deficits in synaptic plasticity and cognition with obesity and diabetes.
|
30886019 |
2019 |
|
Memory impairment
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor.
|
31599329 |
2019 |